Pancreatic Cancer Research

ResearcherKagoshima UniversityNo recent work listed

Kosei Maemura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2090-140X; OpenAlex author ID A5045992734. Sources: OpenAlex.

Their work

Papers
33 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 2 papers · 2014: 1 paper · 2015: 4 papers · 2016: 1 paper · 2017: 5 papers · 2018: 5 papers · 2019: 5 papers · 2020: 4 papers · 2021: 1 paper

Papers 33

  1. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis. Co-author DOI 10.3390/cancers13051057↗
  2. Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal ade… Co-author DOI 10.1007/s00330-019-06517-w↗
  3. Lung recurrence and its therapeutic strategy in patients with pancreatic cancer. First author DOI 10.1016/j.pan.2019.11.015↗
  4. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.07.009↗
  5. Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning. Co-author DOI 10.1158/1078-0432.ccr-19-1247↗
  6. Extracellular volume fraction determined by equilibrium contrast-enhanced multidetector computed tomography as a prognostic factor in unresectable pancreatic a… Co-author DOI 10.1007/s00330-018-5570-4↗
  7. Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8. Co-author DOI 10.1038/s10038-019-0584-6↗
  8. Estimation of Extracellular Volume Fraction With Routine Multiphasic Pancreatic Computed Tomography to Predict the Survival of Patients With Stage IV Pancreati… Co-author DOI 10.1097/mpa.0000000000001427↗
  9. Significance of 18F-Fluorodeoxyglucose (FDG) Uptake in Response to Chemoradiotherapy for Pancreatic Cancer. First author DOI 10.1245/s10434-018-07098-6↗
  10. Gene Regulation by Antitumor miR-204-5p in Pancreatic Ductal Adenocarcinoma: The Clinical Significance of Direct RACGAP1 Regulation. Co-author DOI 10.3390/cancers11030327↗
  11. Corrigendum to "Clinical impact of circulating tumor cells and therapy response in pancreatic cancer" [43 (6) (2017) 1050-1055]. Co-author DOI 10.1016/j.ejso.2018.03.015↗
  12. A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence. First author DOI 10.1097/mpa.0000000000001066↗
  13. Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre-miR-148a on gene regulation. Co-author DOI 10.1111/cas.13610↗
  14. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-018-6357-1↗
  15. Involvement of anti-tumor miR-124-3p and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of ITGA3 and ITGB1 by miR-124-3… Co-author DOI 10.18632/oncotarget.25599↗
  16. Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2017.07.191↗
  17. MicroRNA in pancreatic cancer. Co-author DOI 10.1038/jhg.2016.59↗
  18. ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.13119↗
  19. Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.18261↗
  20. The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster. Co-author DOI 10.18632/oncotarget.19591↗
  21. Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer. First author DOI 10.1007/s00268-016-3477-2↗
  22. Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. First author DOI 10.1016/j.pan.2015.09.015↗
  23. Mucin expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000362↗
  24. Assessment of percutaneous laparoscopic ultrasonography-guided core needle biopsy for the advanced diagnosis of unresectable pancreatic cancer. Co-author DOI 10.6092/1590-8577/2891↗
  25. [Radiotherapy for metastatic lesion of pancreatic cancer]. Co-author PMID 25857007↗
  26. Hypoxia inducible factor-1 alpha plays a pivotal role in hepatic metastasis of pancreatic cancer: an immunohistochemical study. Co-author DOI 10.1002/jhbp.6↗
  27. M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pa… Co-author DOI 10.1097/mpa.0b013e318254f2d1↗
  28. [Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy]. Co-author PMID 24393873↗
  29. Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer. Co-author DOI 10.1002/jso.23020↗
  30. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. First author DOI 10.1007/s00534-011-0400-y↗
  31. Clinical significance of folate receptor β-expressing tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1245/s10434-012-2263-0↗
  32. [A case of pancreatic cancer with liver metastasis controlled effectively by chemotherapy based on chemosensitivity test and stereotactic body radiotherapy]. Co-author PMID 22421785↗
  33. Advanced staging laparoscopy using single-incision approach for unresectable pancreatic cancer. Co-author DOI 10.1097/sle.0b013e31823bae57↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroshi Kurahara · 27 shared papers, 2011–2021 · strength 1.73
  2. Yuko Mataki · 26 shared papers, 2011–2021 · strength 1.55
  3. Shoji Natsugoe · 26 shared papers, 2011–2020 · strength 1.55
  4. Tetsuya Idichi · 9 shared papers, 2017–2021 · strength 0.72
  5. Naohiko Seki · 7 shared papers, 2017–2019 · strength 0.50
  6. Hiroyuki Shinchi · 9 shared papers, 2012–2020 · strength 0.50
  7. Takashi Yoshiura · 5 shared papers, 2017–2020 · strength 0.48
  8. Yoshihiko Fukukura · 5 shared papers, 2015–2020 · strength 0.46
  9. Michiyo Higashi · 5 shared papers, 2013–2020 · strength 0.36
  10. Sonshin Takao · 10 shared papers, 2011–2015 · strength 0.34
  11. Shiho Arima · 3 shared papers, 2019–2020 · strength 0.33
  12. Haruhi Fukuhisa · 4 shared papers, 2018–2019 · strength 0.31
  13. Keiichi Yonemori · 4 shared papers, 2017 · strength 0.29
  14. Masatoyo Nakajo · 2 shared papers, 2019–2020 · strength 0.22
  15. Suguru Yonezawa · 2 shared papers, 2015–2020 · strength 0.14
  16. Seiya Yokoyama · 2 shared papers, 2015–2020 · strength 0.14
  17. Surinder K. Batra · 2 shared papers, 2015–2020 · strength 0.14
  18. Yuto Hozaka · 1 shared paper, 2021 · strength 0.13
  19. Takao Ohtsuka · 1 shared paper, 2021 · strength 0.13
  20. Hiroaki Nagano · 1 shared paper, 2020 · strength 0.11
  21. Qiang Ding · 3 shared papers, 2012–2014 · strength 0.10
  22. Akihide Tanimoto · 1 shared paper, 2020 · strength 0.09
  23. Michael Anthony Hollingsworth · 1 shared paper, 2020 · strength 0.09
  24. Marko Kornmann · 1 shared paper, 2020 · strength 0.09
  25. Koki Maeda · 3 shared papers, 2012–2013 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.